Sangamo Therapeutics, Inc. reported impairment results for the fourth quarter ended December 31, 2023. For the quarter, the company reported Impairment of long-lived assets of $0.3 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.6146 USD | -5.39% | +11.46% | +13.12% |
May. 09 | Transcript : Sangamo Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
May. 09 | Earnings Flash (SGMO) SANGAMO THERAPEUTICS Reports Q1 Revenue $481,000 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.12% | 128M | |
+9.58% | 115B | |
+12.41% | 107B | |
-12.38% | 22.31B | |
-3.67% | 21.6B | |
-3.35% | 18.23B | |
-38.57% | 17.62B | |
+7.51% | 14.26B | |
+35.67% | 12.37B | |
-24.50% | 8.28B |
- Stock Market
- Equities
- SGMO Stock
- News Sangamo Therapeutics, Inc.
- Sangamo Therapeutics, Inc. Reports Impairment Results for the Fourth Quarter Ended December 31, 2023